$ONC

Rosenberg Aaron sold $163K of ONC

Rosenberg Aaron (Chief Financial Officer) sold 631 shares of BeOne Medicines Ltd. (ONC) at $257.74 ($0.16M total) on 2026-06-11.

Original reporting
SEC EDGAR · Rosenberg Aaron
Published Jun 15, 2026, 9:55 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 15, 2026, 9:56 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ONC
Neutral
low confidence
Mentioned
$ONC
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ONCNeutralLow
01

Why it matters

The newest fact is the CFO’s open-market sale and resulting 0-share direct holding; there is no accompanying corporate event in the text.

02

Market read

This provides a fresh, company-specific insider activity datapoint that may slightly influence sentiment but lacks fundamental triggers in the provided text.

03

What to watch

Form 4 sales often do not imply bearish expectations; traders should check for other concurrent insider buys/sales and any upcoming company catalysts (trials, financing, guidance) not present in this text.

Relevance 4/10Novelty 8/10Timing: Filed on 2026-06-15; sale dated 2026-06-11.

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for BeOne Medicines Ltd. (ONC).

Company-level read

Ticker impact

$ONCNeutralLow confidence
Context

SEC Form 4 shows ONC CFO Aaron Rosenberg sold 631 shares in an open-market transaction for about $162.6K, leaving 0 shares.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven rather than a re-rating catalyst.

Evidence & confidence

The filing is a routine Form 4 insider sale with no 10b5-1 plan disclosed and no accompanying company-specific operational or financial news.

Market effects

No sector-level read-across; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

The sale could be unrelated to fundamentals (tax/liquidity/portfolio rebalancing), especially given the small share count and lack of disclosed 10b5-1 plan details.

Key entities

  • BeOne Medicines Ltd.

    Subject of the SEC Form 4 insider transaction disclosure (ONC).

  • Aaron Rosenberg

    Chief Financial Officer who sold 631 shares in an open-market transaction.

Related articles

$ONCHigh

BeOne Medicines Ltd. (ONC): Results of Operations and Financial Condition

BeOne Medicines Ltd. (ONC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-q22026earningsr.htm EX-99.1 Document Exhibit 99.1 BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates • Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year • BRUKINSA (zanubruti

$CRCLMed

Here Are Monday’s Best Wall Street Analyst Research Calls: Atmos Energy, Best Buy, Biogen, Capital One, Costco, Disney, Papa John’s International, Shopify, and More

The article lists Monday analyst calls and market moves. It highlights SK hynix’s Nasdaq debut, up about 12.8% to $168.01 after raising nearly $26.5B. It cites upgrades including BIIB to Buy at $235, COF to Buy at $229, and SHOP to Buy at $160, plus downgrades like BBY to Hold. Circle (CRCL) rose ~15% on OCC approval.

$ONCMed

BeOne Medicines (ONC): Citizens Sees an Inflection Point in Its Cancer Pipeline

Citizens kept a “Market Outperform” rating and $396 price target on BeOne Medicines (NASDAQ:ONC) after the company presented tumor clinical data at ASCO 2026. Citizens highlighted three pipeline programs: BGB-43395 (HR+/HER2- metastatic breast cancer), BG-C9074 (ovarian cancer maintenance), and BGB-B2033 (liver cancer). The target was based on discounted earnings and revenue multiples, with Citizens citing $4.85 billion cash and 88% gross margins.